Arrowhead Pharmaceuticals Inc. (ARWR)
Symbol Info
Listed Symbol ARWR
Name Arrowhead Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-09-30
Latest Fiscal Revenue $16,142,321
Latest Fiscal EPS $-0.66
Price Info
21 Day Moving Average $30.8355
21 Day EMA $32.102350
50 Day Moving Average $31.1135
50 Day EMA $30.749260
200 Day EMA $24.774490
200 Day Moving Average 23.470050
52 Week High $38.75
52 Week Low $10.41
52 Week Change $169.288390
Alpha 0.050924
Beta 1.5923
Standard Deviation 0.245357
R2 0.049670
Periods 60
Share Information
10 Day Average Volume 1,416,692
20 Day Average Volume 1,337,122
30 Day Average Volume 1,445,083
50 Day Average Volume 1,411,849
Outstanding Shares 95,300,992
Float Shares 90,313,005
Percent Float 94.77%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 392
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 22,687,303
Institute Holdings Percent -
Institute Sold Previous 3 Months 7,489,037
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,987,987
Price Change
7 Day Price Change $3.4000015
7 Day Percent Change 10.45%
21 Day Price Change $8.9900020
21 Day Percent Change 33.35%
30 Day Price Change $6.6700000
30 Day Percent Change 22.78%
Month To Date Price Change $7.7700
Month To Date Percent 27.57%
90 Day Price Change $6.320002
90 Day Percent Change 21.33%
Quarter To Date $7.770001
Quarter To Date Percent 27.57%
180 Day Price Change $17.780000
180 Day Percent Change 97.85%
200 Day Price Change $17.650002
200 Day Percent Change 96.45%
Year To Date $23.530000
Year To Date Percent 189.45%
Profile
Description Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Details
Issue Type CS
Market Cap $3,426,070,662
Sec Type EQS
Auditor Rose, Snyder & Jacobs LLP
Total Shares Outstanding 95,300,992
CEO Christopher Anzalone
Employees 95
Last Audit UQ
Classification
CIK 0000879407
Industry Biotechnology
Sector Healthcare
NAICS Research and Development in Biotechnology (except Nanobiotechnology)(541714)
Info
Address 225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
Website http://www.arrowheadpharma.com
Facisimile +1 626 304-3401
Telephone +1 626 304-3400
Email ir@arrowheadpharma.com
Key Ratios
Profitability
EBIT Margin 29.50
EBITDA Margin 32.9
Pre-Tax Profit Margin -15,293
Profit Margin Cont 44.84
Gross Margin -
Profit Margin TOT 44.84
Income Statements
Revenue $125,502,807
Revenue Per Share $1.3169
Revenue 3 Years $566.53
Revenue 5 Years $271.06
Valuation Measures
PE Ratio 74.40
Enterprise Value $3,051,938,271
Price To Sales 27.298758
Price To Free Cash 21.000000
PE High Last 5 Years -
Price To Book 13.2
Price To Cash Flow 19.1
PE Low Last 5 Years -
Price To Tangible Book 15.6
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 2.8
Leverage Ratio 1.7
Quick Ratio 2.7
Long Term Debt To Capital -
Assets
Receivables Turnover 98.3
Invoice Turnover -
Assets Turnover 0.30
Management Effectiveness
Return Assets 20.24
Return On Equity 27.70
Return On Capital 27.70
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ARWR
Arrowhead ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.